CIK 0001534969 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SERA PROGNOSTICS, INC.
Sign in to watch- Ticker
- SERA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 261911522
- Phone
- (801) 990-0520
- Business address
- 2749 E. PARLEYS WAY, SUITE 200, SALT LAKE CITY, UT, 84109
- Former names
- SERA PROGNOSTICS, INC.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,563
- in 6 filings
Net −$79,563. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-10 | Kamdar Kim P. Director | Grant or award | +22,426 | 54,999 | ||
| 2026-07-10 | Kamdar Kim P. Director | Grant or award | +3,421 | 58,420 | ||
| 2026-07-10 | Kamdar Kim P. Director | Grant or award · Stock Option (right to buy) | +34,494 | 34,494 | ||
| 2026-07-10 | Kamdar Kim P. Director | Grant or award · Stock Option (right to buy) | +5,263 | 5,263 | ||
| 2026-07-10 | Capone Mark Christopher Director | Grant or award | +42,404 | 42,404 | ||
| 2026-07-10 | Capone Mark Christopher Director | Grant or award | +1,975 | 44,379 | ||
| 2026-07-10 | Capone Mark Christopher Director | Grant or award · Stock Option (right to buy) | +62,766 | 62,766 | ||
| 2026-07-10 | Capone Mark Christopher Director | Grant or award · Stock Option (right to buy) | +3,037 | 3,037 | ||
| 2026-07-10 | Lawrence Sandra AJ Director | Grant or award | +22,426 | 38,899 | ||
| 2026-07-10 | Lawrence Sandra AJ Director | Grant or award | +2,276 | 41,175 | ||
| 2026-07-10 | Lawrence Sandra AJ Director | Grant or award · Stock Option (right to buy) | +34,494 | 34,494 | ||
| 2026-07-10 | Lawrence Sandra AJ Director | Grant or award · Stock Option (right to buy) | +3,501 | 3,501 | ||
| 2026-07-10 | CRITCHFIELD GREGORY C Director | Grant or award | +22,426 | 845,292 | ||
| 2026-07-10 | CRITCHFIELD GREGORY C Director | Grant or award | +1,594 | 846,886 | ||
| 2026-07-10 | CRITCHFIELD GREGORY C Director | Grant or award · Stock Option (right to buy) | +34,494 | 34,494 | ||
| 2026-07-10 | CRITCHFIELD GREGORY C Director | Grant or award · Stock Option (right to buy) | +2,452 | 2,452 | ||
| 2026-06-11 | Inglis Tiffany Eul Davis Chief Medical Officer | Sale | −362 | $2.01 | $728 | 92,075 |
| 2026-06-11 | Anderson Dyaarl Lee Jr. Chief Commercial Officer | Sale | −4,739 | $2.01 | $10K | 77,998 |
| 2026-06-11 | Aerts Austin Chief Financial Officer | Sale | −2,037 | $2.01 | $4K | 301,190 |
| 2026-06-11 | Lindgardt Zhenya Chief Executive Officer | Sale | −6,990 | $2.01 | $14K | 865,009 |
Page 2 of 7 · 130 trades